Very good results today particularly on slowing of disease progression which is the most important aspect. MRIs we're great but would like to see images. The only small negative is the dichotomy between pain results and structural results (synovial fluids and other markers). There is a way to go before approval but the results continue to demonstrate that FDA approval is inevitable and likely for DMOAD. The share price will take care of itself.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-66
-
- There are more pages in this discussion • 321 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $101.6K | 424.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144266 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 18540 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |